Dr. Gary V. Burton
Claim this profileLSU Health Sciences Center at Shreveport
Area of expertise
Breast Cancer
Gary V. Burton has run 15 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Gary V. Burton has run 10 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
LSU Health Sciences Center At Shreveport
Ochsner LSU Health Monroe Medical Center
Clinical Trials Gary V. Burton is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting
1 award
N/A
More about Gary V. Burton
Clinical Trial Related
2 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Gary V. Burton has experience with
- Paclitaxel
- Exemestane
- Cyclophosphamide
- Biospecimen Collection
- Nivolumab
- Radiation Therapy
Breakdown of trials Gary V. Burton has run
Breast Cancer
Breast cancer
Brain Tumor
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary V. Burton specialize in?
Gary V. Burton focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Gary V. Burton currently recruiting for clinical trials?
Yes, Gary V. Burton is currently recruiting for 7 clinical trials in Shreveport Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Gary V. Burton has studied deeply?
Yes, Gary V. Burton has studied treatments such as Paclitaxel, Exemestane, Cyclophosphamide.
What is the best way to schedule an appointment with Gary V. Burton?
Apply for one of the trials that Gary V. Burton is conducting.
What is the office address of Gary V. Burton?
The office of Gary V. Burton is located at: LSU Health Sciences Center at Shreveport, Shreveport, Louisiana 71103 United States. This is the address for their practice at the LSU Health Sciences Center at Shreveport.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.